Subacute sclerosing panencephalitis epidemiology and demographics

Revision as of 14:55, 14 December 2012 by Prashanthsaddala (talk | contribs)
Jump to navigation Jump to search

Subacute sclerosing panencephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Subacute sclerosing panencephalitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Subacute sclerosing panencephalitis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Subacute sclerosing panencephalitis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Subacute sclerosing panencephalitis epidemiology and demographics

CDC on Subacute sclerosing panencephalitis epidemiology and demographics

Subacute sclerosing panencephalitis epidemiology and demographics in the news

Blogs on Subacute sclerosing panencephalitis epidemiology and demographics

Directions to Hospitals Treating Subacute sclerosing panencephalitis

Risk calculators and risk factors for Subacute sclerosing panencephalitis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

SSPE has been reported in all parts of the world, but in western countries it is considered a rare disease.

Fewer than 10 cases per year are reported in the United States, a dramatic decrease that followed the nationwide measles immunization program. However, in some countries like India, over 2 cases of SSPE per 100,000 people are reported each year.

SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself. 1 in 100,000 people infected with measles are at risk.

References


Template:WH Template:WS